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From April 2008 to November 2008, many cases of hepatitis A were reported in 
Seoul and Gyeonggi Province in Korea. Furthermore, the rate of severe or fulmi-
nant hepatitis have significantly increased during the latest epidemic (13.4% vs. 
5.2%, p=0.044). Therefore, widespread use of vaccine is warranted to reduce the 
burden of hepatitis A in Korea.
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In Korea, hepatitis A is a disease that must be reported to the district public health 
authority. Since April 2008, the incidence of hepatitis A has increased, particularly 
in Seoul and the adjacent areas in Gyeonggi Province (Fig. 1).1 Therefore, we con-
sidered this as an epidemic of hepatitis A. At that time, more patients with hepatitis 
A have been admitted to Severance Hospital, a tertiary teaching hospital in Seoul, 
Korea (Fig. 2). During this period, many physicians felt that severity, mortality and 
complications of hepatitis A increased compared with previous period. In the pres-
ent study, we analyzed clinical features of acute hepatitis A patients who were hos-
pitalized during the latest epidemic. The aim of the present study was to verify an 
increment of severe cases in recent hepatitis A epidemic and to discuss strategies 
to prevent hepatitis A in Korea. 
We retrospectively reviewed medical records of 245 acute hepatitis A patients 
who were admitted to Severance Hospital between January 2006 and November 
2008, and compared clinical manifestations of hepatitis A observed during the lat-
est epidemic (from April 2008 to November 2008, period 1) with previous one 
(from January 2006 to March 2008, period 2). Patients who were transferred from 
other provinces or were suspected to have acquired hepatitis A virus (HAV) in for-
eign countries were excluded. The diagnosis of acute hepatitis A was made by the 
detection of serum IgM antibody against HAV along with clinical manifestations. 
Commercially available enzyme immunoassays (Abbott Laboratories, North Chica-
go, IL, USA) were used to detect IgM anti-HAV, anti-HCV, HBsAg and antibody 
to HBsAg. Patients with prothrombin time less than 40% compared to the control Clinical Features of Hepatitis A
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were considered significant. Statistical analysis was per-
formed using SPSS for Windows, version 12.0 (SPSS Inc., 
Chicago, IL, USA). This study was approved by the institu-
tional review board of the hospital. 
Among our patients, 132 cases of hepatitis A were detect-
ed during period 1 (111 cases per 10,000 hospital admis-
sions), and 113 cases during period 2 (30 cases per 10,000 
hospital admissions). A total of 224 patients were finally in-
cluded in this analysis after excluding 21 patients who were 
referred from other provinces or suspected to have acquired 
HAV in foreign countries.
The demographic characteristics of patients with hepatitis 
A are listed in Table 1. The majority of patients were in their 
thirties (31-40 years, 46.5%) during period 1, whereas the 
majority of patients were in their twenties (21-30 years, 
41.2%) during period 2. Moreover, the rate of patients in 
teens (11-20 years, 3.9%) during period 1 was greatly re-
duced compared with period 2 (13.4%). It seems that re-
duced proportions of age group moved to thirties or forties, 
suggesting that the pattern of acute hepatitis A is changing 
from small outbreaks in crowding areas such as school or 
military, to large-scale outbreaks in community. The major-
and without hepatic encephalopathy were defined as having 
severe acute hepatitis (AHs).2 Fulminant hepatitis (FH) was 
defined as less than 40% prothrombin time compared to the 
control and also presentation of hepatic encephalopathy.3 
Limited acute hepatitis (AH) were those with prothrombin 
time more than 40% compared to the control, and without 
hepatic encephalopathy. Complications included acute re-
nal failure (ARF), prolonged cholestatic hepatitis, hemolyt-
ic anemia, gastrointestinal bleeding, acalculous cholecystitis, 
pancreatitis and autoimmune hepatitis (antinuclear antibody 
titer >1:160 or positive smooth-muscle antibody titer >1:80 
and compatible liver biopsy findings). ARF was defined as 
an increase in serum creatinine concentration to ≥0.5 mg/dL 
or by 50% compared with the baseline value.4 Prolonged 
cholestatic hepatitis was defined as having clinical jaundice 
lasting for at least 12 weeks, with a peak of bilirubin >10 
mg/dL.5 Continuous data were reported as mean±SD, and 
the Student’s t-test was employed to compare parametric 
data. Nonparametric data were analyzed with Mann-Whit-
ney U-test. Categorical variables were reported as frequen-
cy distributions, and Chi-square or Fisher’s exact tests were 
performed. All p values were two-tailed, and p values <0.05 
Fig. 1. Reported annual number of hepatitis A patients in Seoul and Gyeonggi Province. 
Fig. 2. Monthly incidence of hospitalization for hepatitis A in Severance Hospital. 
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developed 18 complications associated with hepatitis A. 
One patient in period 1 had ARF with hemolytic anemia, 
and one patient in period 2 experienced ARF and gastroin-
testinal bleeding simultaneously. No patient died during 
both periods. The proportion of severe cases (severe or ful-
minant hepatitis A) was significantly higher in period 1 
ity of patients were males in both period 1 (63.8%) and pe-
riod 2 (61.9%). Hepatitis A incidence of males was approx-
imately twice higher than that of females. However, there is 
no evidence to indicate that males are more susceptible to 
HAV than females.6 The differences between males and fe-
males may be related to risk activities such as hand wash-
ing and contaminated food ingestion. The underlying dis-
ease including hypertension, diabetes and chronic liver 
diseases were less prevalent in period 1, although it was sta-
tistically insignificant. The path of infection was obscure 
for most patients. The most frequently reported symptoms 
included myalgia, nausea, vomiting and abdominal pain, 
and there were no significant differences between the two 
groups (Table 2). The laboratory tests (leukocyte and plate-
let counts, hemoglobin, serum aspartate transaminase, ala-
nine tranasaminase, bilirubin and albumin) on admission 
day or at its worst values did not show significant differenc-
es between the two groups (Table 3). However, C-reactive 
protein at the time of admission was slightly higher in peri-
od 1 (2.73±3.26 vs. 1.56±1.86, p=0.012. The clinical com-
plications and outcomes are shown in Table 4. Sixteen pa-
tients (11 patients in period 1 and 5 patients in period 2) 
Table 1. Demographic Characteristics and Presumed Etiology of Hepatitis A Patients
Total (n=224) Period 1 (n=127) Period 2 (n=97)
Mean age (yrs) 31±8 31±7 30±9
Age distributions (yrs)
    -10     2 (0.9)     1 (0.8)   1 (1.0)
    11-20   18 (8)     5 (3.9) 13 (13.4)
    21-30   92 (41.1)   52 (40.9) 40 (41.2)
    31-40   97 (43.3)   59 (46.5) 38 (39.2)
    41-    15 (6.7)   10 (7.9)   5 (5.2)
Gender (male)  141 (62.9)   81 (63.8) 60 (61.9)
Underlying disease
     No underlying disease 206 (92) 120 (94.5) 86 (88.7)
     Hypertension      6 (2.7)     2 (1.6)   4 (4.1)
     Diabetes      5 (2.2)     1 (0.8)   4 (4.1)
     Non-hepatobiliary malignancy     2 (0.9)     1 (0.8)   1 (1)
     Others      7 (3.1)     3 (2.4)   4 (4.1)
     Liver disease   18 (8)     7 (5.5) 11 (11.3)
        B-viral carrier   15 (6.7)     6 (4.7)   9 (9.3)
        C-viral carrier     1 (0.4)     1 (0.8)   0 (0)
        Liver cirrhosis, B-viral      1 (0.4)     0 (0)   1 (1)
        Liver cirrhosis, C-viral      1 (0.4)     0 (0)   1 (1)
        Hepatocellular carcinoma     0 (0)     0 (0)   0 (0)
Presumed etiology
    Raw fish or shellfish ingestion   44 (19.6)   23 (18.1) 21 (21.6)
    Close contact with patients   11 (4.9)     8 (6.3)   3 (3.1)
    Unknown  169 (75.4)   96 (75.6) 73 (75.3)
Values are presented as mean±standard deviation or as number (%).
Table 2. Symptoms and Severity of Hepatitis A Patients
Period  1 (n=127) Period  2 (n=97)
Headache    29 (22.8) 14 (14.4)
Myalgia   99 (78) 72 (74.2)
Anorexia   39 (30.7) 36 (37.1)
Nausea, vomiting   68 (53.5) 66 (68)
Abdominal pain    39 (30.7) 40 (41.2)
Diarrhea    10 (7.9) 10 (10.3)
Dark urine   26 (20.5) 26 (26.8)
Encephalopathy      2 (1.6)   1 (1)
Severity 
    AH 110 (86.7) 92 (94.8)
    AHs   15 (11.8)   5 (5.2)
    FH     2 (1.6)   0 (0)
AH, limited acute hepatitis; Ahs, severe acute hepatitis; FH, fulminant 
hepatitis.
Values are presented as number (%).Clinical Features of Hepatitis A
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compatible with cholestatic hepatitis.
During the recent decades, the incidence of hepatitis A in 
Korea has decreased along with rapidly improved sanita-
tion and living standards, thanks to the nation’s economic 
growth.7 In Korea, the immunity to HAV in adults over the 
age of 30 years was 100% in the 1980s and more than 97% 
in 1999.8 Therefore, acute hepatitis A in adults was consid-
ered uncommon, and testing for anti-HAV antibody in adults 
(13.4 vs. 5.2%, p=0.044). However, the duration of admis-
sion, the rate of complications and mortality did not in-
crease. Looking at the age distribution of severe cases, se-
vere cases are limited to patients in their twenties or thirties. 
Particularly, during period 1, more than 10% of patients in 
these age groups experienced severe forms of hepatitis. 
Liver biopsy was performed in two patients, and both of 
them showed portal inflammation and bridging necrosis, 
Table 3. Biochemical Characteristics of Hepatitis A Patients
Period  1 (n=127) Period  2 (n=97) p value*
WBC, /mm
3 6,004±3,699 5488±2216 0.196
Hemoglobin, mg/dL 15±2 15±2 0.247
Platelet (admission), ×10
3/mm
3 180±70 197±84 0.099
Platelet (lowest), ×10
3/mm
3 176±72 191±87 0.072
AST (admission), IU/L 2,823±3,110 2,182±2,648 0.105
AST (peak), IU/L 3,352±3,406 2,733±3,188 0.170
ALT (admission), IU/L 3,097±2,415 2,675±2,055 0.16
ALT (peak), IU/L 3,472±2,460 3,151±2,191 0.313
Total bilirubin (admission), mg/dL 4.7±4.5 4.3±2.6 0.424
Total bilirubin (peak), mg/dL 6.8±5.1 6.2±3.1 0.251
Albumin, mg/dL  4.0±0.5 4.1±0.4 0.220
ALP, IU/L 185±85 211±110 0.051
INR (admission) 1.3±0.4 1.2±0.5 0.025
INR (peak) 1.4±0.4 1.3±1.2 0.008
CRP, mg/dL 2.73±3.26 1.56±1.86 0.012
WBC, white blood cell; AST, aspartate transaminase; ALT, alanine transaminase; ALP, alkaline phosphatase; CRP, C-reactive protein; AH, 
limited acute hepatitis; AHs, severe acute hepatitis; FH, fulminant hepatitis. 
Values are presented as mean±standard deviation.
*Values by Student’s t-test or Mann-Whitney U-test. 
Table 4. Outcomes of Hepatitis A 
Period  1 (n=127) Period  2 (n=97) p value
Duration of admission (days) 8±5  9±5   0.112*
Severe cases (AHs or FH)    17 (13.4%)      5 (5.2%) 0.044
    Age distributions (yr) 
         -10   0/1 (0%)   0/1 (0%)
         11-20   0/5 (0%) 0/13 (0%)
         21-30 9/52 (17.3%) 2/40 (5.0%)
         31-40 8/59 (13.6%) 3/38 (7.9%)
         41- 0/10 (0%)   0/5 (0%)
Complications     11 (8.7%)      5 (5.2%) 0.434
    Acute renal failure      9 (7.1 %)      5 (5.2 %) 0.592
    Prolonged cholestatic hepatitis      1 (0.8%)      0 (0%) 1.0
    Hemolytic anemia      1 (0.8%)      0 (0%) 1.0
    Gastrointestinal bleeding      1 (0.8 %)      1 (1.0%) 1.0
    Acalculous cholecystitis      0 (0%)      0 (0%) -
    Pancreatitis       0 (0%)      0 (0%) -
    Autoimmune hepatitis      0 (0%)      0 (0%) -
Mortality       0 (0%)      0 (0%) -
AH, limited acute hepatitis; AHs, severe acute hepatitis; FH, fulminant hepatitis.
Values are presented as mean±standard deviation or as number (%).
*Value by Student’s t-test.Hee Kyoung Choi, et al.
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plications occurred in 10 patients during the recent epidemic. 
The hepatitis A virus may serve as a trigger for autoimmune 
hepatitis in genetically susceptible people. However, there 
was no case of autoimmune hepatitis associated with hepa-
titis A in this study. Fulminant hepatitis, which occurs in 
less than 1% of the cases, appears to be more frequent in 
adults than in children.22,23 Previously, disease severity was 
considered to be linked to individual host factors such as 
age and underlying liver disease. Older age is classically re-
lated to greater morbidity and mortality of hepatitis A. How-
ever, it is not clear whether this is due directly to liver failure 
or to decompensation caused by underlying diseases.24 In 
the case of the Shanghai epidemic, factors that contributed 
to mortality in patients with severe diseases included age of 
>40 years and other comorbid conditions (e.g., chronic hep-
atitis C).25 In this study, however, patients with underlying 
liver disease or age of >40 years did not show differences 
in clinical outcomes. Although more patients were in severe 
conditions during the latest epidemic, we did not observe 
any change in mortality. It is quite likely due to the fact that 
some mortality cases transferred from other district were 
excluded from this analysis. Although mortality was not 
significantly different between the two periods, more pa-
tients in period 1 experienced severe hepatitis and more pa-
tients were hospitalized. Therefore, the morbidity of hepati-
tis A in the period 1 is not negligible. 
Hepatitis A vaccine has not been routinely recommended 
as part of the childhood immunization scheme in Korea. 
Vaccination has been recommended for people in high risk 
groups, including travelers to areas where hepatitis A is en-
demic, people with occupational exposure to the virus, in-
jection drug users, patients with chronic liver disease, ho-
mosexual individuals, and people who live in communities 
with cyclic epidemics. A need for more widespread use of 
hepatitis A vaccine is growing in countries with transitional 
epidemiology such as Korea. In Korea, vaccination of peo-
ple with high risks is recommended, but not refunded by 
the public health system. Immunoglobulin such as post-ex-
posure prophylaxis has not been widely used in this coun-
try. However, many people who were hospitalized for severe 
hepatitis A were young and did not have related risk factors. 
Implementing the current recommendations for vaccination 
would not have prevented most of complications and deaths 
occurred during period 1. Without measures that increases 
immunity to hepatitis A in young adults, future epidemics 
with severe consequences such as the one described herein, 
should be expected. 
was not recommended, even in high risk patients. As hy-
giene conditions improved, transmission factors have been 
under control, keeping children from being exposed to the 
virus. Such children became a large adult population with 
no immunity to HAV. The seroprevalence of anti-HAV has 
been steadily declined among children. Low rates of IgG 
anti-HAV have been observed, particularly in the age group 
of 10-24 years, which matches with the age group of acute 
hepatitis A patients who were identified through the recent-
ly increased incidence in Korea.9 Since the seroprevalence of 
anti-HAV has been decreasing among adults in Korea,10,11 
there is a substantial potential for severe morbidity and 
mortality during sporadic outbreaks. In this study, the high-
est incidence was observed in patients in their twenties or 
thirties, and this was concordant with previous reports pub-
lished in Korea.10-12 Once they are infected, they develop se-
vere hepatitis.7,13-15 In this study, patients in these age groups 
are likely to experience severe symptoms. These changes 
have an impact on morbidity because the severity of symp-
toms increases with the age of the infected individual. Thus, 
as natural immunity in the population decreases, particular-
ly in children and young adults, the number of susceptible 
individuals increases, enhancing the likelihood of hepatitis 
A outbreaks. A large and increasing number of hepatitis A 
patients in Korea can be attributable to the increased sus-
ceptibility of the population, especially in young people. 
Another possible reason is the increased virus circulation 
in the community, leading to community-wide spread of in-
fection and outbreaks in different groups through various 
transmission routes. Transportation of goods and people 
from highly endemic areas has introduced a spread of HAV 
virus. Genotyping of the virus has not yet been performed 
during period 1, but is planned. Until the late 1990s, a single 
HAV genotype IA strain has been detected in Korea. Recent-
ly, a new genotype IIIA was found to co-circulate with geno-
type IA strains in Korea. Moreover, it has been suggested 
that more various types of strains might have been import-
ed from highly endemic countries.16 Similar epidemiologi-
cal changes have been seen in many countries worldwide.17 
Recent hepatitis A epidemics in urban areas of industrial-
ized countries have not been traced to a common source.18-20 
Thus, effective prevention of HAV infection has become in-
creasingly important. Similarly, we were unable to identify 
risk factors for transmission in more than 75% of patients. 
Although the majority of hepatitis A cases are self-limit-
ed acute hepatitis, some develop into severe forms of hepa-
titis or cause unexpected complications.21 Extrahepatic com-Clinical Features of Hepatitis A
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changing epidemiology of hepatitis A in children and the consider-
ation of active immunization in Korea. Yonsei Med J 2000;41:34-9.
8. Choi W, Eom HS, Kim IH, Lee DH, Kim PS, Kim HG, et al. Pat-
terns of acute hepatitis A and anti-HAV seroprevalence of kyungin 
province. Korean J Gastroenterol 1999;34:69-75.
9. Kim TY, Sohn JH, Ahn SB, Son BK, Lee HL, Eun CS, et al. 
[Comparison of recent IgG anti-HAV prevalence between two 
hospitals in Seoul and Gyeonggi area]. Korean J Hepatol 2007; 
13:363-9.
10. Song HJ, Kim TH, Song JH, Oh HJ, Ryu KH, Yeom HJ, et al. 
Emerging need for vaccination against hepatitis A virus in patients 
with chronic liver disease in Korea. J Korean Med Sci 2007;22: 
218-22.
11. Lee D, Cho YA, Park Y, Hwang JH, Kim JW, Kim NY, et al. Hep-
atitis a in Korea: epidemiological shift and call for vaccine strate-
gy. Intervirology 2008;51:70-4.
12. Lee EJ, Kwon SY, Seo TH, Yun HS, Cho HS, Kim BK, et al. 
[Clinical features of acute hepatitis A in recent two years]. Korean 
J Gastroenterol 2008;52:298-303.
13. Rakela J, Redeker AG, Edwards VM, Decker R, Overby LR, 
Mosley JW. Hepatits A virus infection in fulminant hepatitis and 
chronic active hepatitis. Gastroenterology 1978;74:879-82.
14. Poovorawan Y, Theamboonlers A, Sinlaparatsamee S, Chaiear K, 
Siraprapasiri T, Khwanjaipanich S, et al. Increasing susceptibility 
to HAV among members of the young generation in Thailand. 
Asian Pac J Allergy Immunol 2000;18:249-53.
15. Byun KS, Kim JH, Song KJ, Baek LJ, Song JW, Park SH, et al. 
Molecular epidemiology of hepatitis A virus in Korea. J Gastroen-
terol Hepatol 2001;16:519-24.
16. Yun H, Kim S, Lee H, Byun KS, Kwon SY, Yim HJ, et al. Genetic 
analysis of HAV strains isolated from patients with acute hepatitis 
in Korea, 2005-2006. J Med Virol 2008;80:777-84.
17. Jenson HB. The changing picture of hepatitis A in the United 
States. Curr Opin Pediatr 2004;16:89-93.
18. Shaw FE Jr, Sudman JH, Smith SM, Williams DL, Kapell LA, 
Hadler SC, et al. A Community-wide epidemic of hepatitis A in 
Ohio. Am J Epidemiol 1986;123:1057-65.
19. Skinner JT. Community-wide epidemic of hepatitis A--Shelby 
County, Tennessee. J Tenn Med Assoc 1995;88:468-9.
20. Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepa-
titis A: recent experience in a community teaching hospital. J In-
fect Dis 1995;171 Suppl 1:S15-8.
21. Cuthbert JA. Hepatitis A: old and new. Clin Microbiol Rev 
2001;14:38-58.
22. Lemon SM, Shapiro CN. The value of immunization against hep-
atitis A. Infect Agents Dis 1994;3:38-49.
23. Brown GR, Persley K. Hepatitis A epidemic in the elderly. South 
Med J 2002;95:826-33.
24. Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, 
Kelley PW. Frequency of illness associated with epidemic hepatitis 
A virus infections in adults. Am J Epidemiol 1985;122:226-33.
25. Halliday ML, Kang LY, Zhou TK, Hu MD, Pan QC, Fu TY, et al. 
An epidemic of hepatitis A attributable to the ingestion of raw 
clams in Shanghai, China. J Infect Dis 1991;164:852-9.
The limitation of the study is relatively small population. 
Therefore, further research needs to be conducted with a 
large cohort of patients, in order to properly document com-
plications and management of the disease. Our findings 
may not be generalized, considering biases related to which 
patients sought medical care and which physicians chose to 
hospitalize them. We were unable to assess patients who 
were not hospitalized. We could not apply a molecular epi-
demiologic approach due to limitation of samples. Most pa-
tients were reported with obscure etiology, and we could 
not identify transmission route in this study. It could be ex-
plained as one of the characteristics of recent urban epi-
demic, however, it could also be one of limitations of our 
study related to retrospective nature. 
In conclusion, although the majority of hepatitis A patients 
completely recovered during period 1, many patients had to 
be hospitalized or developed associated complications. Hep-
atitis A may become a major public health issue in years to 
come. Changes in epidemiological pattern would increase 
the disease burden, may cause large-scale community-wide 
outbreaks and result in higher healthcare costs. Therefore, 
prevention of the disease requires not only strengthening 
young adult’s immunity to hepatitis A through vaccination, 
but also conducting intensive public awareness campaigns 
and detailed interventions in the course of transmission. 
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